Side-by-side · Research reference
DihexavsHexarelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED7/28 cited
BPhase 1HUMAN-REVIEWED19/45 cited
Dihexa
Angiotensin IV Analogue · Pre-Clinical
Not established — animal studies only
Hexarelin
Hexapeptide GHRP · Cardio-tropic
SQ · Multiple sites · 1–3×/day
01Mechanism of Action
Parameter
Dihexa
Hexarelin
Primary target
c-Met receptor (HGF receptor tyrosine kinase)
Ghrelin receptor (GHS-R1a) + cardiac CD36Smith 1996Ghigo 1997
Pathway
HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization
GHS-R1a → Gαq → Ca²⁺ → GH release. CD36 engagement → direct cardio-tropic actionGhigo 1997
Downstream effect
Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models
Strong GH pulse + IGF-1 elevation; cardio-protective effects in animal MI modelsGhigo 1997
Origin
Small-molecule angiotensin IV analogue designed to activate HGF/c-Met systemWright 2015
Synthetic hexapeptide His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂Smith 1996
Antibody development
—
—
02Dosage Protocols
Parameter
Dihexa
Hexarelin
Human dosing
Not established — no human trials
—
Animal studies
Mouse/rat models only — dosing not translatable to humans
—
Clinical status
No Phase 1, 2, or 3 trials published
—
Frequency
—
1–2× per day max (tachyphylaxis with chronic 3× daily)
Lower / starter dose
—
50 mcg per dose
Duration
—
4–8 weeks on / 4–8 weeks off (tachyphylaxis mitigation)
Reconstitution
—
Bacteriostatic water
Timing
—
Pre-sleep + fasted preferred
04Side Effects & Safety
Parameter
Dihexa
Hexarelin
Human safety data
None available — no human clinical trials
—
Theoretical c-Met risks
c-Met receptor activation has been implicated in tumorigenesis; unknown cancer risk profile
—
Pre-clinical tolerability
Not systematically reported in available studies
—
Hunger
—
Strong appetite increase via ghrelin agonism
IGF-1 elevation
—
Strong; monitor with chronic high-dose use
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis)
Pregnancy / OB
—
Avoid
Absolute Contraindications
Dihexa
- ·Not approved for human use — research compound only
Hexarelin
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
Dihexa
- ·Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)
Hexarelin
- ·Untreated diabetes
- ·Severe hyperprolactinemia
05Administration Protocol
Parameter
Dihexa
Hexarelin
1. Human administration
No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
2. Legal status
Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.
SQ — abdomen or thigh. Rotate sites.
3. Timing
—
Pre-sleep + fasted preferred. Cycle on/off to avoid tachyphylaxis.
4. Storage
—
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
—
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
Dihexa
— no documented stacks
Hexarelin
+ CJC-1295 (no DAC)
StrongHexarelin (GHRP) + CJC-1295-no-DAC (GHRH analogue) is the higher-amplitude variant of the standard GHRH+GHRP stack. Hexarelin produces a stronger pulse than ipamorelin but with cortisol + prolactin signal — choose this stack for maximum GH amplitude when side-effect tolerance is acceptable. Cycle aggressively.
- Hexarelin
- 100 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- Maximum GH pulse amplitude (with side-effect signal)